Home・Lista de Ações・AnaptysBio Inc

AnaptysBio Inc

Fechado

SetorSaúde

56.23 3.14

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

55.79

Máximo

56.6

Indicadores-chave
By Trading Economics
Rendimento	-102M -53M
Vendas	-83M 26M
EPS	-1.843
Margem de lucro	-206.934
Funcionários	104
EBITDA	-99M -31M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+42.5% upside

Dividendos
By Acuity
Próximos Ganhos	11 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-388M 1.6B
Abertura anterior	53.09
Fecho anterior	56.23

Sentimento de Notícias

By Acuity

50%

128 / 340 Ranking em Healthcare

AnaptysBio Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de ago. de 2026, 19:26 UTC

AnaptysBio Inc. shares are trading higher today, continuing a trend since Thursday's close, despite notable volatility during the session.

5 de ago. de 2026, 19:36 UTC

AnaptysBio Inc. shares are lower in Wednesday's session, having declined from earlier highs amid routine market fluctuations and trading near the lower end of its recent range.

3 de ago. de 2026, 20:06 UTC

AnaptysBio Inc shares are higher today, recovering from earlier losses amid a broader market rally in the S&P 500 and Nasdaq 100 indices.

31 de jul. de 2026, 20:06 UTC

AnaptysBio Inc shares are lower, reflecting broader market weakness amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 de jul. de 2026, 23:36 UTC

AnaptysBio Inc. shares declined after-market, reflecting ongoing weakness amid broader market volatility and the Federal Reserve's interest rate decisions.

29 de jul. de 2026, 19:56 UTC

Macro Event

AnaptysBio Inc shares are higher, recovering from an earlier dip, amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

28 de jul. de 2026, 23:16 UTC

AnaptysBio Inc shares are higher in after-market trading, recovering from earlier lows. No specific news was identified to explain the movement.

24 de jul. de 2026, 19:16 UTC

AnaptysBio Inc shares are lower today, reflecting a decline since Thursday. Broader market sentiment is affected by recent volatility in oil prices.

23 de jul. de 2026, 09:16 UTC

AnaptysBio Inc is trading lower in pre-market hours amid broader market pressures from disappointing earnings reports and rising geopolitical tensions.

22 de jul. de 2026, 22:16 UTC

AnaptysBio Inc shares are higher in after-market hours, trading above Wednesday's close amid broader market concerns over rising crude oil prices and U.S.-Iran tensions.

21 de jul. de 2026, 20:12 UTC

AnaptysBio Inc. shares are lower in after-market trading, continuing a downward trend and positioning the stock below its 20-day moving average.

20 de jul. de 2026, 23:01 UTC

AnaptysBio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Comparação entre Pares

Variação de preço

AnaptysBio Inc Previsão

Preço-alvo

By TipRanks

42.5% parte superior

Previsão para 12 meses

Média 80.67 USD 42.5%

Máximo 95 USD

Mínimo 70 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para AnaptysBio Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para AnaptysBio Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

128 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.